Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 5
Submit an article Journal homepage
613
Views
10
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study

Yaser AlkhatibDivision of Hematology and Medical Oncology, Henry Ford Hospital, Detroit, MI, USA; Correspondence[email protected]
,
Zaid Abdel RahmanDepartment of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA
&
Philip KuriakoseDivision of Hematology and Medical Oncology, Henry Ford Hospital, Detroit, MI, USA;
Pages 1130-1134 | Received 25 Mar 2016, Accepted 18 Sep 2016, Published online: 05 Oct 2016

References

  • Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–276.
  • Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin lymphoma classification project. Ann Oncol. 1998;9:717–720.
  • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
  • Feugier P, Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126.
  • Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–1461.
  • Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33:322–326.
  • Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–1625.
  • Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8:909–915.
  • Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8:88–96.
  • Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, et al. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol. 2009;11:455–459.
  • Shi WY, Xiao D, Wang L, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012;3:e275.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Fang Z, Xu X, Zhou Z, et al. Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells. Mol Med Rep. 2014;9:2251–2256.
  • Leclerc GM, Leclerc GJ, Kuznetsov JN, et al. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS One. 2013;8:e74420
  • Hoffman AE, Demanelis K, Fu A, et al. Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2013;22:736–744.
  • Koo YX, Tan DS, Tan IB, et al. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52:1509–1516.
  • Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–5502.
  • Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–2323.
  • Terret C, Albrand G, Rainfray M, et al. Impact of comorbidities on the treatment of non-Hodgkin lymphoma: a systematic review. Expert Rev Hematol. 2015;8:329–341.
  • Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol. 2014;165:489–496.
  • Rush University Medical Center, Metformin in combination with standard induction therapy for large B-cell lymphoma (DLBCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000; [cited 2016 Mar 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531308 NLM Identifier: NCT02531308.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.